Sepsis Diagnostics Market By Product Type (Instruments, Assay Kits and Reagents, Blood Culture Media), By Technology Type (Microbiology, Molecular Diagnostics, Immunoassays, Flow Cytometry), By Testing Type (Laboratory Testing, PoC Testing), By Region And Companies - Industry Segment Outlook, Market Assessment, Competition Scenario, Trends, And Forecast 2023-2032

Report Overview

Sepsis Diagnostics Market size is expected to be worth around USD 1.8 Bn by 2032 from USD 0.9 Bn in 2022, growing at a CAGR of 7.8% during the forecast period from 2023 to 2032.

The global Sepsis Diagnostics market is expected to see robust growth in the coming years. Sepsis is a life-threatening condition caused by the body’s immune response to infection, affecting over 30 million people worldwide each year. The timely diagnosis and treatment of sepsis is crucial, as patient outcomes deteriorate rapidly once sepsis progresses. The sepsis diagnostics market is comprised of laboratory tests and platforms that help detect sepsis early on and identify the causative pathogen.

Driving factors

Globally Increasing Incidence of Hospital-Acquired Infections (HAIs)

Also known as nosocomial infections, hospital-acquired infections are infections that occur during a hospital stay. These infections pose a substantial challenge to global healthcare information systems. Contributing to the increase in HAIs are the increased use of invasive medical procedures, the growing population of immunocompromised patients, and the emergence of drug-resistant pathogens. As a result, the prevalence of HAIs is a significant factor in the demand for effective sepsis diagnostics.

Most common healthcare-associated infections (HAIs)

Urinary tract infections (UTIs), pneumonia, and sepsis are among the most prevalent types of HAIs. Catheter use frequently results in UTIs, whereas pneumonia can be caused by ventilator-associated infections. If left untreated, both UTIs and pneumonia can progress to sepsis. Due to the severity and life-threatening nature of sepsis, a prompt diagnosis is essential. Identification and management of these common HAIs are primary forces behind the development and widespread adoption of sepsis diagnostic products. The Sepsis Diagnostics Market, a critical subset of Infectious Disease In Vitro Diagnostics, is poised for significant expansion globally.

In immunocompromised and chronically ill patients

Immune-compromised or chronically ailing patients are more susceptible to HAIs and subsequent sepsis. This population is comprised of individuals undergoing chemotherapy, recipients of organ transplants, and patients with conditions such as diabetes or HIV/AIDS. These patients require frequent hospitalizations and invasive procedures, which increases their susceptibility to infection. In these high-risk individuals, sepsis diagnostics play a crucial role in the early detection and treatment of sepsis.

The incidence of sepsis among hospitalized patients

The incidence of sepsis among hospitalized patients has consistently increased in the United States. Recent statistics indicate an alarming annual increase of 8.7%. This trend can be attributed to a number of factors, including an aging population, the rise of drug-resistant pathogens, and the prevalence of chronic diseases. To address this growing public health concern, accurate and timely diagnostics for sepsis are essential.

Increasing Demand for Diagnostic Products for Sepsis Due to the Rapid Rise in HAIs

Rapid global growth in HAIs has led to a corresponding increase in demand for sepsis diagnostic products. In order to enhance patient outcomes and lessen the burden of sepsis, healthcare providers and institutions are recognizing the significance of early detection and intervention. Innovative diagnostic technologies, such as biomarker-based assays and rapid point-of-care tests, have increased the need for dependable sepsis diagnostic tools.

Restraining Factors

Exorbitant Price of Molecular Diagnostic Tests

In the sepsis diagnostics market, the high price of molecular diagnostic assays is a significant obstacle. Some healthcare providers are unable to afford these tests due to the high cost of specialized apparatus and reagents, limiting their ability to provide timely and accurate sepsis diagnosis.

Budgetary Constraints of Government Hospitals and Academic Laboratories

It is difficult for government hospitals and academic laboratories to invest in automated diagnostic devices and other necessary instruments for sepsis diagnosis due to budget constraints. This limitation impedes the ability to provide optimal care and timely treatment to patients with sepsis in these settings.

Insufficiency of Qualified Healthcare Professionals

Diagnosis and treatment of sepsis are hindered by the worldwide scarcity of qualified medical professionals. Inadequate sepsis-management-trained healthcare professionals result in delayed diagnoses and substandard care, negatively affecting patient outcomes.

Insufficient Trained Paramedics

Significant concern exists regarding the deficiency of trained paramedics capable of recognizing the early symptoms of sepsis. In identifying and initiating treatment for sepsis, paramedics play a crucial role; however, a lack of specialized training in the recognition of sepsis results in ignored or delayed diagnoses.

Increasing Demand for Automated Molecular Diagnostic Devices

Molecular diagnostics-based automated devices offer high accuracy in sepsis detection, but their effective operation requires specialized training and knowledge. These devices are inaccessible to many healthcare providers due to their expense and complexity, which hinders their widespread adoption.

Product Analysis

Blood Culture Media Segment Dominates the Market for Sepsis Diagnostics. Blood culture media are an integral part of sepsis diagnostics, as they are used to culture and identify bacteria or fungi present in the patient's blood sample. This section contains a variety of blood culture media, including conventional, automated, and specialized media.

In the segment of blood culture media, the adoption of sophisticated technologies that can improve the precision and efficacy of blood culture diagnostics is on the rise. Consumers are pursuing products that detect and identify pathogens more quickly and with a greater degree of sensitivity. In addition, there is a growing demand for blood culture media that are user-friendly and readily incorporated into existing laboratory workflows.

Technology Analysis

By Technology Analysis of the Market for Sepsis Diagnostics Market Segment for Microbiology Dominates. The microbiology segment concentrates on the various sepsis diagnostics technologies. This includes conventional microbiological techniques such as blood culture and gram staining in addition to advanced techniques such as polymerase chain reaction (PCR), nucleic acid amplification tests (NAATs), mass spectrometry, and immunological assays.

Within the realm of microbiology, there has been a surge in consumer curiosity regarding the diverse microbial ecosystem and its implications for human health, primarily catalyzed by technological advancements in this field. In the Sepsis Diagnostics Market, automated microbiology plays a pivotal role in early sepsis detection, allowing for rapid and accurate assessment of blood cultures to improve patient outcomes. This burgeoning interest is rooted in the growing recognition of microbiota's significant influence on various health conditions, underscored by the potential for personalized interventions.

Pathogen Type Analysis

Market for Sepsis Diagnostics: Bacterial Sepsis Segment Dominates. Multiple pathogens, including bacteria, fungi, viruses, and parasites, can cause sepsis. The segment on bacterial sepsis emphasizes specifically diagnostics associated with bacterial infections. It involves the identification and characterization of bacterial pathogens responsible for sepsis using a variety of testing techniques.

In the segment of bacterial sepsis, consumer behavior is influenced by the critical need for a prompt and accurate diagnosis. Consumers have a growing demand for diagnostic instruments and technologies that can rapidly detect the presence of bacterial pathogens in circulation, allowing for prompt treatment interventions. There is a preference for point-of-care testing options that provide prompt results and reduce the time required for diagnosis and treatment.

Testing Type Analysis

Dominates the Sepsis Diagnostics Market is the Laboratory Testing Segment. The laboratory testing section describes the diagnostic tests performed in clinical laboratories to diagnose sepsis. Blood culture, microbial identification and susceptibility testing, molecular diagnostics, immunoassays, and biomarker analysis are included.

Overall, laboratory testing is experiencing a transition toward increased consumer participation and empowerment. With the rise of direct-to-consumer testing, individuals are exercising greater control over their health by gaining access to a variety of laboratory tests without a physician's referral. In response to consumer demand for convenience, accessibility, and affordability in laboratory testing services, online platforms with comprehensive test menus and streamlined sample collection have emerged.

Key Market Segments

By Product Type

• Instruments
• Assay Kits and Reagents
• Blood Culture Media
• Others (Software, etc.)

By Technology Type

• Microbiology
• Molecular Diagnostics
• Immunoassays
• Flow Cytometry

By Pathogen Type

• Bacterial Sepsis
• Gram-Positive Bacteria
• Gram-Negative Bacteria
• Fungal Sepsis
• Others

By Testing Type

• Laboratory Testing
• PoC Testing

Growth Opportunity

Potential for Growth in the Sepsis Diagnostics Market Driven by Opportunity

The diagnosis of sepsis is of utmost importance, as the condition can rapidly deteriorate and result in septic shock and organ failure. Due to the increased mortality risk associated with delayed antibiotic therapy, it is crucial that healthcare professionals make an accurate diagnosis as soon as feasible. Fortunately, swift diagnostic techniques can reduce diagnosis turnaround time and enhance patient outcomes.

Many sepsis diagnostics manufacturers are channeling their investments into point-of-care technology to streamline and enhance early sepsis diagnosis, which is poised to not only drive expansion in the sepsis diagnostics sector but also open up lucrative opportunities for companies specializing in rapid diagnostic tests.

Automatic Detection for Swifter Outcomes

The automated diagnostic assays BACTEC Plus, BacT/Alert, and BACTEC FX can detect sepsis in as little as three hours. This automated detection method is a significant advancement in the diagnosis of sepsis because it drastically reduces the turnaround time for test results. By automating the process, the tests require minimal healthcare professional intervention and can be readily incorporated into existing diagnostic workflows.

Biomarkers Display Promising Outcomes

Procalcitonin and lactate biomarker assays have demonstrated promising results for early sepsis detection. By measuring the levels of specific biomolecules in the blood, these tests provide healthcare professionals with a more accurate evaluation of the patient's immune response. By utilizing biomarkers, healthcare professionals are able to diagnose sepsis at an earlier stage, thereby improving patient outcomes.

Imaging Techniques Aid in Siagnosing Sepsis

Ultrasounds and computed tomography (CT) scans can also aid in sepsis diagnosis. These tests can be utilized to determine the source of the infection causing sepsis and the extent of the damage. By precisely identifying the source of an infection, medical professionals are able to administer targeted antibiotic therapy and thereby prevent septic shock and organ failure.

Early Diagnosis and Treatment

Recognizing and treating sepsis early can prevent septic distress and organ failure. For this reason, advances in sepsis diagnostics are essential for enhancing patient outcomes. As sepsis becomes a greater concern, healthcare professionals and manufacturers are investing in new technologies to enhance sepsis diagnosis.

Latest Trends

Major Market Tendencies Shaping the Market for Sepsis Diagnostics

Sepsis is a potentially fatal disease that has the potential to affect anyone. Multiple agents, including bacteria, viruses, and fungi, can cause it. If left untreated, sepsis can cause severe organ damage and lead to mortality. In the past, sepsis diagnosis was time-consuming and accuracy was not always guaranteed. Nonetheless, with the introduction of swift diagnostic or point-of-care techniques, the market for sepsis diagnostics has witnessed a radical transformation. We will examine some of the main market trends that are presently shaping the sepsis diagnostics market, such as the increasing adoption of rapid diagnostic or point-of-care techniques, the focus of key companies on developing advanced technologies, and the worldwide increase in the prevalence of sepsis.

Increasing Adoption of Point-of-Care or Rapid Diagnostic Techniques

Increasing adoption of rapid diagnostic or point-of-care techniques is one of the main factors driving demand in the sepsis diagnostics market. These methods are available for use anywhere, from laboratories to healthcare facilities, and are quicker and more accurate than conventional methods. With enhanced turnover time, healthcare professionals can make rapid, well-informed clinical decisions that can potentially save lives.

Principal Businesses Focus on Developing Innovative Technologies

Some of the leading companies in the sepsis diagnostics market are concentrating on the development of cutting-edge technologies that enhance the testing's speed, standardization, and efficacy. These cutting-edge technologies promise to make sepsis diagnosis faster and more accurate than ever before. They include the creation of biosensors, sequencing of the next generation, and molecular diagnostics technologies.

Rapid Techniques Enhance Velocity, Standardization, and Effectiveness

The healthcare industry is increasingly adopting rapid diagnostic techniques due to their speed, standardization, and efficacy. These procedures are intended to provide rapid and accurate results that aid in the diagnosis of sepsis. Point-of-care platforms are increasingly incorporating rapid diagnostic methods, which can reduce the turnaround time for test results from hours to minutes.

Demonstrating Dependable and Rapid Outcomes

Rapid diagnostic techniques are acquiring market share due to their dependability and speedy results. These technologies have demonstrated high rates of accuracy in diagnosing sepsis when tested. As every minute contributes toward enhancing patient outcomes, accuracy, and speed are essential in sepsis diagnosis.

Demand for Early Diagnosis Increases

The successful management of sepsis requires an early diagnosis. Rapid diagnostic techniques are especially useful for detecting sepsis early, thereby enhancing patient outcomes. There is a growing demand for rapid diagnostic methods that provide rapid and accurate results for early diagnosis.

Regional Analysis

In 2021, North America will emerge as the global market in terms of revenue share exceeding 39.7%. As the year 2021 comes to a close, we pause to consider the trends that have shaped the global market landscape over the past 12 months. The emergence of North America as the preeminent participant in the global market is a significant change that has disrupted traditional market dynamics.

North America is home to a large and diverse market that provides ample expansion and growth opportunities for businesses. The region's expansive consumer market and high disposable income are a major draw for businesses seeking to expand their customer base. North America is also a region with diverse cultures, interests, and preferences, making it an ideal location for businesses seeking to enter new markets and diversify their product offerings.

The technologically sophisticated infrastructure of North America also contributes to the continent's dominant position on the global market. The United States, Canada, and Mexico have made substantial investments in the development of cutting-edge technological infrastructure, such as 5G, artificial intelligence, and the internet of things. These cutting-edge technologies have revolutionized business operations, augmenting their efficacy, output, and profitability.

North America's dominance of the global market is further bolstered by its flourishing business climate. Governments in the region have been proactive in developing regulations and incentives that promote business growth. These policies foster innovation and entrepreneurship, allowing businesses to expand and prosper in a competitive market. In addition, the region's legal and financial systems are transparent and trustworthy, giving businesses the confidence they need to operate effectively.

Key Regions and Countries

North America

• US
• Canada
• Mexico

Western Europe

• Germany
• France
• The UK
• Spain
• Italy
• Portugal
• Ireland
• Austria
• Switzerland
• Benelux
• Nordic
• Rest of Western Europe

Eastern Europe

• Russia
• Poland
• The Czech Republic
• Greece
• Rest of Eastern Europe

APAC

• China
• Japan
• South Korea
• India
• Australia & New Zealand
• Indonesia
• Malaysia
• Philippines
• Singapore
• Thailand
• Vietnam
• Rest of APAC

Latin America

• Brazil
• Colombia
• Chile
• Argentina
• Costa Rica
• Rest of Latin America

Middle East & Africa

• Algeria
• Egypt
• Israel
• Kuwait
• Nigeria
• Saudi Arabia
• South Africa
• Turkey
• United Arab Emirates
• Rest of the Middle East & Africa

Key Players Analysis

The market for sepsis diagnostics is expanding exponentially, as sepsis continues to be a leading cause of morbidity and mortality worldwide. The diagnosis and treatment of sepsis must be administered promptly in order to reduce the mortality rate associated with this condition. Several market leaders in sepsis diagnostics are developing innovative and dependable instruments for the early detection of sepsis.

BioMerieux, a global leader in in vitro diagnostics, is one of the market leaders in sepsis diagnostics. The company provides a variety of diagnostic instruments for the swift and accurate diagnosis of sepsis. Their VITEK® MS system is a trustworthy instrument for accurate microbial identification, whereas their BacT/ALERT® 3D system is a trustworthy blood culture system for sepsis diagnosis.

Roche Diagnostics, another prominent player, offers a variety of sepsis testing solutions, such as the Cobas® DNA Sample Preparation reagent and the Cobas® Liat® System. These innovative diagnostic instruments provide a rapid and accurate diagnosis of sepsis, allowing clinicians to treat patients in a timely manner.

Becton, Dickinson and Company, Thermo Fisher Scientific, Inc., Abbott Laboratories, and T2 Biosystems are a few of the other major players in the sepsis diagnostics market. These companies are investing significantly in research and development to bring to market innovative sepsis diagnostic instruments.

Top Key Players in smart contact lenses Market

• Abbott Laboratories
• Becton, Dickinson and Company
• bioMérieux SA
• Hoffmann-LA Roche Ltd
• Beckman Coulter, Inc.
• Thermo Fisher Scientific Inc.
• Cepheid Inc.
• Bruker Corporation
• Nanosphere, Inc.
• Immunexpress Inc.
• Luminex Corporation
• Response Biomedical Corp.
• T2 Biosystems, Inc.
• Danaher Corporation
• Sysmex Corporation

Recent Development

In June 2023, Asep Medical (Asep) unveiled a groundbreaking AI technology for the rapid detection of infections associated with severe sepsis. This innovative method was developed under the supervision of Dr. Robert Hancock, the Killam Professor at the University of British Columbia in Canada.

In 2023, The US Food and Drug Administration (FDA) approved the SepsisOMICs test, a molecular test that can identify the specific pathogen causing sepsis within hours.

In 2023, A study published in the journal Nature Medicine identified a new sepsis biomarker, called soluble TREM-1, that is more accurate than traditional biomarkers such as white blood cell count and C-reactive protein.

Report Scope: